Collectively, these findings reveal that ER+ breast cancer cell lines with INPP4B overexpression exhibit increased sensitivity to the FDA-approved Wnt inhibitor pyrvinium or 4-OHT-pyrvinium combination treatment, and thus repurposing pyrvinium may be a therapeutic strategy to consider for this subset of breast cancers. Here, INPP4B is linked to breast carcinoma.